5914 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5914)
  2. GSK Faculty (5697)
  3. Department of Medicine (4259)
  4. Department of Pathology and Laboratory Medicine (3037)
  5. Tow Center for Developmental Oncology (TCDO) (2613)
  6. Solid Tumor Oncology Division (2600)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1744)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2527)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5914)
  2. GSK Faculty (5697)
  3. Department of Medicine (4259)
  4. Department of Pathology and Laboratory Medicine (3037)
  5. Tow Center for Developmental Oncology (TCDO) (2613)
  6. Solid Tumor Oncology Division (2600)

More Groups

People
  1. Marc Ladanyi (1327)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (120)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (263)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (758)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5914)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomics-based immuno-oncology: Bridging the gap between immunology and tumor biology
    Review

    DiNatale, R. G.; Hakimi, A. A.; Chan, T. A.
    Human Molecular Genetics (2020)

    Fulltext@MSK | Save
  • Targeting KRAS(G12C): From inhibitory mechanism to modulation of antitumor effects in patients
    Editorial

    Kim, D.; Xue, J. Y.; Lito, P.
    Cell (2020)

    Fulltext@MSK | Save
  • PD-L1 blockade therapy: Location, location, location
    Editorial

    Brown, C. C.; Wolchok, J. D.
    Cancer Cell (2020)

    Fulltext@MSK | Save
  • Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Journal Article

    Garrido-Castro, A. C.; Saura, C.; Barroso-Sousa, R.; Guo, H.; Ciruelos, E.; Bermejo, B.; Gavilá, J.; Serra, V.; Prat, A.; Paré, L.; more...
    Breast Cancer Research (2020)

    Fulltext@MSK | Save
  • HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation
    Journal Article

    van der Ploeg, K.; Le Luduec, J. B.; Stevenson, P. A.; Park, S.; Gooley, T. A.; Petersdorf, E. W.; Shaffer, B. C.; Hsu, K. C.
    Blood Advances (2020)

    Fulltext@MSK | Save
  • JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F(-) MPNs
    Journal Article

    Pastore, F.; Krishnan, A.; Hammaren, H. M.; Silvennoinen, O.; Yan, B.; Levine, R. L.
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
    Journal Article

    Mata, D. A.; Benhamida, J. K.; Lin, A. L.; Vanderbilt, C. M.; Yang, S. R.; Villafania, L. B.; Ferguson, D. C.; Jonsson, P.; Miller, A. M.; Tabar, V.; more...
    Acta Neuropathologica Communications (2020)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Activating alterations of p110 subunits determine PI3K isoform selectivity in prostate cancer
    Meeting Abstract

    Zhang, Z.; Mao, N.; Lee, Y. S.; Li, D.; Rosen, N.; Sawyers, C.; Carver, B.
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save